Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| House Dust Mite Allergy Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for House Dust Mite Allergy Overview | 7 | 1 |
| House Dust Mite Allergy Therapeutics under Development by Companies | 8 | 1 |
| House Dust Mite Allergy Pipeline Products Glance | 9 | 3 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| House Dust Mite Allergy Products under Development by Companies | 12 | 1 |
| House Dust Mite Allergy Companies Involved in Therapeutics Development | 13 | 6 |
| ALK-Abello A/S | 13 | 1 |
| Anergis SA | 14 | 1 |
| Biomay AG | 15 | 1 |
| Circassia Pharmaceuticals Plc | 16 | 1 |
| HAL Allergy BV | 17 | 1 |
| Stallergenes SAS | 18 | 1 |
| House Dust Mite Allergy Therapeutics Assessment | 19 | 7 |
| Assessment by Monotherapy Products | 19 | 1 |
| Assessment by Combination Products | 20 | 1 |
| Assessment by Target | 21 | 1 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Drug Profiles | 26 | 13 |
| AllerDM Drug Profile | 26 | 1 |
| Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis Drug Profile | 27 | 1 |
| BM-35 Drug Profile | 28 | 1 |
| PL-103 Drug Profile | 29 | 1 |
| standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract Drug Profile | 30 | 2 |
| standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine Drug Profile | 32 | 5 |
| Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis Drug Profile | 37 | 2 |
| House Dust Mite Allergy Dormant Projects | 39 | 1 |
| House Dust Mite Allergy Discontinued Products | 40 | 1 |
| House Dust Mite Allergy Product Development Milestones | 41 | 11 |
| Featured News &Press Releases | 41 | 1 |
| Apr 27, 2016: Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK house dust mite SLIT-tablet, ACARIZAX | 41 | 1 |
| Apr 13, 2016: License application for investigational house dust mite SLIT-tablet accepted for review by FDA | 42 | 1 |
| Apr 12, 2016: Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet | 42 | 1 |
| Jan 27, 2016: Marketing authorisation for ACARIZAX issued in France | 42 | 1 |
| Dec 09, 2015: New product (ACARIZAX) for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark | 43 | 1 |
| Nov 26, 2015: New medicine for house dust mite allergic rhinitis now available in Japan | 44 | 1 |
| Nov 19, 2015: Desensitization Therapy Actair House Dust Mite Sublingual Tablets Launched in Japan | 44 | 1 |
| Jun 09, 2015: ALK s partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal | 45 | 1 |
| Jun 04, 2015: ALK announces top-line results from its partner MSD's North American Phase III trial of house dust mite SLIT-tablet | 46 | 1 |
| Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet | 46 | 1 |
| Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study | 47 | 1 |
| Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet | 48 | 1 |
| Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development | 49 | 1 |
| Mar 04, 2014: Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet | 50 | 1 |
| Sep 12, 2013: Circassia's house dust mite allergy treatment achieves long-term symptom reduction | 51 | 1 |
| Appendix | 52 | 2 |
| Methodology | 52 | 1 |
| Coverage | 52 | 1 |
| Secondary Research | 52 | 1 |
| Primary Research | 52 | 1 |
| Expert Panel Validation | 52 | 1 |
| Contact Us | 52 | 1 |
| Disclaimer | 53 | 1 |